ContactContact
Internationalisation of the business and optimisation of production processes
€76.0mn
Equity investment
€51mn
Revenues 2019 (preliminary)
273
Employees 2019

KEY FACTS AT A GLANCE

  • Internationalisation of the business and optimisation of production processes
  • Expansion of manufacturing capacities and direct sales organisation
  • Ramp-up of patented lightweight implants 

POLYTECH HEALTH & AESTHETICS GMBH

Investment by
DBAG FUND VI

€76.0MN

DBAG'S INTEREST

€14.4mn

MANAGEMENT BUYOUT
Shareholders:
DBAG FUND VI

80.1%

EQUITY SHARE BELONGING TO DBAG

15.2%

other shareholders

19.9%

First invested

OCTOBER 2016

REVENUES in €mn

 

36

 

2017

 

42

 

2018

 

51

 

2019 (preliminary)

As of 30 June 2020

We help Polytech to focus squarely on further developing the implants for medical use and to highlight its excellent “Made in Germany” seal of quality. The fact that we were able to find a solution to the future of this family-owned company by means of a management buyout is once again evidence of the high esteem in which we are held by German SMEs.

TOM ALZIN
MANAGING DIRECTOR

PROFILE

Polytech is a leading player in Europe in the development and production of silicone implants and is the sole German manufacturer of such products. The company specialises in breast implants used in reconstructive surgery after illness and in aesthetic plastic surgery.

The company has grown strongly in recent years. This expansion is based on production (under clean-room conditions) in Germany, which conforms to the highest quality standards, and the company’s innovative capacity. Polytech has developed surface textures for its products that lead to a clear reduction in the rate of complications.

POTENTIAL FOR DEVELOPMENT

In view of the very positive response to implants “Made in Germany”, Polytech has considerably expanded its sales activities. At the moment, the company generates around 40 per cent of its revenues in Germany and around 30 per cent in other European countries. However, its implants are increasingly being distributed worldwide, currently in over 70 countries. Polytech serves a growth market, driven by a number of factors including rising prosperity and demographic change in industrialised countries.

FINANCIAL YEAR 2019

Since the beginning of the investment, Polytech has continued on its path with sustained growth dynamics; the company is also planning to achieve higher sales in the 2019 financial year than in the previous year. This is due to market share gains in the economic area of Europe, the Middle East and Africa, especially in Germany and Italy. They are based on Polytech's leading and innovative product portfolio, which was further broadened by the merger with G&G Biotechnology in 2018. G&G had developed the world's first breast implant with reduced weight (lightweight implants).

OUTLOOK AND OBJECTIVES

The merger with G&G Biotechnology should enable Polytech to further strengthen its leading market position in Europe and to expand internationally. In order to be able to meet the increasing demand in the future, the company is working on further expanding its capacities. In 2020, sales and earnings are expected to be higher than in the previous year, based on the planned stronger market penetration of the new lightweight implants and a more intensive cultivation of existing markets.

Responsible team member

Tom Alzin
Tom Alzin

Managing Director

Tom Alzin
Name:
Tom Alzin
Telephone:
+49 69 95787-219
E-Mail:

Tom Alzin

Managing Director

Tom Alzin joined Deutsche Beteiligungs AG in 2004 and became a Managing Director in 2011.

He holds a degree in Business Administration from the HEC Lausanne, and also studied at the London School of Economics and Political Science.

Tom Alzin has 15 years of experience in private equity. During that time, he gained a wealth of knowledge, particularly in the mechanical and plant engineering and in the services sector. Tom Alzin was involved in numerous acquisitions and realisations and also in the IPO of Homag. The realisations of Homag and Spheros, subsequent to their very successful development, are two of his most successful transactions. Tom Alzin also led the investment process in FDG, Pfaudler, Schülerhilfe, Telio, Polytech, duagon, Kraft & Bauer and Cartonplast and sits on the advisory councils of the companies, which are still part of the DBAG portfolio.

Current portfolio companies

Cartonplast Holding GmbH Telio Management GmbH Polytech Health & Aesthetics GmbH Pfaudler International S.à r.l.

Former portfolio companies

Tom Alzin

Managing Director

+49 69 95787-219
tom.alzin(at)dbag.de